Logo Image
Opinion|Videos|June 27, 2024

Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

Episodes in this series
  1. What are the current guideline-recommended systematic treatments for HR-positive/HER2-negative (HR+/HER2-) breast cancer?
  2. What are some of the differences between the CDK 4/6 inhibitors used in the management of HR+/HER2-? What factors drive treatment decision-making between available options? 

Related Content